Agentic AI for Pharma Executives

Pharmaceutical companies run on documents: protocols, site communications, case reports, submissions, deviations, and records that must be complete, traceable, and inspectable. That workload is enormous, rule-bound, and audited, which makes it an unusually good fit for agents and an unusually demanding one. This guide gives pharma executives the sequence, what validation implies, and where qualified human accountability is non-negotiable.

Where is the documentation burden worth attacking?

Area	Agent work	Qualified human decision
Clinical trial operations	Site communications, document collection and completeness checks, query preparation, status reporting	Protocol decisions; medical judgment
Regulatory affairs	Submission document assembly, formatting and completeness checks, cross-reference verification	Content, strategy, and attestations
Pharmacovigilance	Case intake structuring, field extraction, duplicate detection, completeness checks	Causality, seriousness, reportability
Quality	Deviation documentation, CAPA packet assembly, training record checks	Disposition and approval
Medical information	Draft responses from approved content	Approval and release of medical content
Manufacturing records	Batch documentation checks, discrepancy identification	Batch release
Commercial operations	Non-promotional administrative work within policy	Promotional content and claims

FISTA's AI in clinical trials guide covers trial-specific use cases.

What does validation imply?

Computerized systems used in regulated activities carry expectations for documented intended use, risk-based validation, data integrity, audit trails, access control, and change management. Applied to agents, that means:

• Documented intended use per agent, with a risk assessment proportionate to its role.
• Testing evidence on representative real cases, retained, with acceptance criteria defined in advance. An evaluation set serves this purpose and should be built as a validation artifact.
• Traceability: attributable, contemporaneous records of inputs, outputs, versions, reviewer changes, and approvals.
• Controlled change: prompts, tools, models, and configurations under change control with revalidation triggers, including provider model updates.
• Access control and segregation of duties between preparation and approval.

The provider-driven model update is the requirement most teams miss: a model version changing underneath a validated system is a change, and the change-control process must anticipate it. The model deprecation risk management guide covers the mechanics; the AI evaluation explained for executives piece covers the testing evidence. This is general guidance, not regulatory advice; involve quality assurance and regulatory affairs from design.

Which decisions stay with qualified people?

Causality and seriousness assessments in safety, reportability decisions, batch release, protocol and medical judgments, promotional content approval, and regulatory attestations. Agents prepare, structure, check, and draft; qualified individuals decide and sign, and the record shows who did what. Executives should insist that every deployment document states this boundary explicitly.

What does the audit trail need to contain?

What the agent received, what it produced, which version and configuration produced it, what a reviewer changed, who approved the final output, and when, retained per record-keeping requirements and retrievable for inspection. Designing this in is straightforward; retrofitting it under inspection pressure is not. The AI observability explained for executives piece describes the tracing that makes it possible.

How should quality and regulatory functions be involved?

At design, not at deployment. The pattern that works: quality and regulatory define the intended use, the risk classification, and the acceptance criteria before the build; engineering builds the evaluation set to those criteria; validation documentation is produced as the system is built rather than assembled afterward; and change control covers the agent from the first release. Companies that deploy first and involve quality later usually rebuild.

What should pharma executives measure?

Document cycle times in trials and regulatory affairs; query resolution times; safety case intake time to complete record; deviation documentation cycle time; medical information response times; inspection and audit findings related to records; and qualified staff hours returned from administration to judgment work.

What are the common mistakes?

Treating agents as unregulated productivity tools when they touch regulated activities; building without quality involvement; no change control for provider model updates; audit trails added late; and pilots on regulated processes that can never be validated as built. The remedy for all five is the same: classify intended use first, involve quality at design, and build validation artifacts as you go.

What should pharma executives ask?

• For each agent, what is the documented intended use and risk classification?
• Which regulated activities does it touch, and who signs the output?
• What happens when the model provider updates the version we validated?
• Could we produce the audit trail for any output an inspector selects?
• Have quality and regulatory affairs reviewed the design, not just the result?

How can FISTA Solutions help life sciences companies?

FISTA Solutions builds AI agents for documentation-heavy life sciences operations with intended-use documentation, evaluation sets built as validation evidence, complete audit trails, access control, and change control including provider model updates, and works with executives, quality, and regulatory teams through its AI enablement practice. Since 2017, FISTA has delivered 150+ projects for 50+ companies across 12+ countries.

To scope a documentation deployment your quality function will accept, talk to FISTA on WhatsApp, or read the general counsel's guide to AI and agentic AI for the contracting side.